drugset / Trial / NCT04564937
The Study of Drug SCT510A in Patients With Wet Age-related Macular Degeneration (wAMD)
Non-randomizedSequentialOpen-labelTreatment
Summary
Multicenter ，open-label, multi-dose study to evaluate the safety and tolerability in patients with wAMD treated with intravitreal recombinant humanized anti-VEGF monoclonal antibody（SCT510A）
Timeline
- Start
- 2020-11-06
- Primary completion
- 2022-04-30
- Completion
- 2022-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SCT510A | Monoclonal antibody | 0.625 mg | Intravitreal |
| Subject | SCT510A | Monoclonal antibody | 1.25 mg | Intravitreal |
| Subject | SCT510A | Monoclonal antibody | 2 mg | Intravitreal |
| Subject | SCT510A | Monoclonal antibody | 2.5 mg | Intravitreal |